There are substantial inter-individual differences in biological aging trajectories, but the origin of these
differences is unclear. One specific cellular component that sustains life and fuels stress adaptation are
mitochondria, which contain their own genome and generate metabolic intermediates necessary for epigenetic
modifications. As a result, genetic defects in mitochondria shorten lifespan in both animal models and patients
with mtDNA defects, possibly via the influence of mitochondrial signaling on gene expression and the
epigenetic machinery, which includes DNA methylation (DNAm). Reliable changes in DNAm occur with
advancing age at specific genomic locations, which have been captured and integrated in predictive algorithms
called epigenetic clocks. These clocks predict DNAmAge and have been validated and meta-analyzed in large
human cohorts demonstrating that DNAmAge predicts mortality and age-related diseases. But little is known
about what clocks actually measure (i.e., what makes them tick), and about their modifiability by metabolic
factors across the lifespan. To map the life-long behavior of epigenetic clocks and their responses to both
stress mediators and mitochondrial dysfunction, we have developed a primary human fibroblasts cellular
lifespan model where: i) DNAm signatures of aging are conserved, ii) the rate of DNAm aging is accelerated
about 70 times relative to the human body, iii) metabolic and mitochondrial dysfunction reduces lifespan (i.e.,
the Hayflick limit) by 25-50%, and iv) other aging biomarkers including ccf-mtDNA and the pro-inflammatory
cytokine IL6 are also progressively induced across the cellular lifespan. In Aim 1, we will characterize DNAm
aging trajectories across the entire cellular lifespan in both female and male cells using four different global
DNAmAge algorithms, a gene-based approach, and by modeling single-CpG trajectories. There results will be
validated and extended into available human aging cohorts. In Aim 2, we will examine the modifiability of
DNAm clocks with two interventions that reliably decrease the Hayflick limit: i) we will use converging
pharmacological and genetic approaches to induce specific mitochondrial respiratory defects, and ii) expose
cells to chronic glucocorticoid stimulation to recapitulate the effects of chronic psychosocial stress known to
accelerate biological aging in humans. In the final aim, we will perform studies to understand how clock-based
DNAmAge relate to other validated aging biomarkers including the expression of age-related genes (Elovl2,
p16INK4a), telomere length, circulating cell-free mtDNA (ccf-mtDNA), and the inflammatory cytokine IL-6.
Moreover, additional experiments will be performed to establish the contribution of cell division to epigenetic
age acceleration, the role of ambient oxygen, and to test the effect of a DNA demethylation agent on other
aging biomarkers and on lifespan. Overall, these studies will uncover novel longitudinal associations between
epigenetic clocks and human aging biomarkers, and establish the role of mitochondrial signaling as a driver of
cellular aging in a human system.